Metabolic Syndrome & Insulin Resistance Protocol
Metabolic Syndrome & Insulin Resistance Protocol framework focused on consistent execution, practical monitoring, and safer progression.
A protocol targeting the five components of metabolic syndrome — central obesity, hypertriglyceridemia, low HDL, hypertension, and insulin resistance — through GLP-1 receptor agonism, AMPK activation, mitochondrial enhancement, and adipose tissue remodeling.
Who it's for
Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.
Free Peptide Guide
Metabolic Syndrome & Insulin Resistance Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Protocol at a Glance
Cycle Duration
Minimum 24 weeks; reassess HbA1c, fasting insulin, lipid panel, waist circumference at 12-week intervals
Target Audience
Adults with confirmed metabolic syndrome (3+ diagnostic criteria), pre-diabetes (HbA1c 5.7-6.4%), or obesity-associated insulin resistance
| Compound | Dose | Frequency |
|---|---|---|
| Liraglutide Liraglutide: GLP-1 agonist; improves insulin secretion, reduces hepatic glucose output, decreases central adiposity; lower dose than Ozempic for metabolic optimization | 0.6 mg escalating to 1.2-1.8 mg | Once daily SC |
| Exenatide Exenatide: dual GLP-1/GIP mechanism; reduces postprandial glucose excursions; synergistic with liraglutide for comprehensive incretin augmentation | 5-10 mcg | Twice daily SC before meals |
| AICAR AICAR: AMPK activator mimicking exercise; improves skeletal muscle glucose uptake; inhibits hepatic VLDL production reducing triglycerides | 50 mg | Daily SC |
| 5-Amino-1MQ 5-Amino-1MQ: NNMT inhibitor; elevates adipose NAD+; reduces adipocyte size and improves adipokine profile; targets visceral adiposity specifically | 250 mg | Once daily oral |
| MOTS-c MOTS-c: activates AMPK in muscle, liver, and adipose; improves insulin sensitivity across all metabolic tissues; declines with aging, worsening metabolic syndrome | 5-10 mg | Daily SC |
| NAD+ NAD+: corrects mitochondrial dysfunction driving beta-cell decline; SIRT1/3 activation improves insulin signaling; complements AICAR via separate AMPK-sirtuin pathways | 500 mg NMN | Once daily oral |
Free Peptide Guide
Metabolic Syndrome & Insulin Resistance Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.
Daily Schedule
Morning
Baseline review and first execution window
Log sleep, energy, and tolerance; complete planned Liraglutide timing if scheduled.
Midday
Adherence and symptom check
Review hydration, workload, and side effects before any changes.
Evening
Recovery closeout and next-day setup
Record outcomes, maintain schedule consistency, and prepare next-day protocol.
Safety
- Escalating side effects or new concerning symptoms require prompt clinical review.
- Avoid abrupt multi-compound changes during unstable periods.
- Maintain regular follow-up with a licensed clinician throughout the cycle.
Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.
Who should avoid
- Anyone using this protocol without qualified medical supervision
- People with unstable medical or psychiatric conditions without specialist guidance
- Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Common Mistakes
Changing multiple variables at once
Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.
How to fix: Keep one-variable changes per review cycle and log response for several days.
Ignoring adherence and recovery fundamentals
Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.
How to fix: Protect daily anchors first, then optimize protocol details gradually.
FAQ
How long should Metabolic Syndrome & Insulin Resistance Protocol run before reassessment?
A common window is Minimum 24 weeks; reassess HbA1c, fasting insulin, lipid panel, waist circumference at 12-week intervals, with periodic review of tolerance and objective trends.
Can I increase complexity quickly for faster results?
Usually no. Safer optimization comes from staged changes and clear tracking.
What should I track each day?
Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.
Key Takeaways
- Consistency with Liraglutide + Exenatide execution matters more than frequent protocol changes.
- Single-variable adjustments improve safety and decision quality.
- Objective daily tracking supports better long-term outcomes.
Why This Stack Works
Metabolic syndrome is driven by insulin resistance in adipose, muscle, and liver tissue, creating a self-reinforcing cycle of ectopic fat deposition, inflammation, and further insulin signaling impairment. Liraglutide and Exenatide provide GLP-1 receptor agonism to improve insulin secretion, reduce hepatic glucose output, slow gastric emptying, and reduce central adiposity. AICAR activates AMPK to mimic caloric restriction effects without food restriction — improving glucose uptake in muscle and inhibiting hepatic lipogenesis. 5-Amino-1MQ elevates intracellular NAD+ specifically in adipose tissue by inhibiting NNMT, reducing adipocyte size. MOTS-c activates AMPK in all metabolic tissues to improve insulin sensitivity. NAD+ corrects the mitochondrial dysfunction central to beta-cell decline and insulin resistance progression.
Clinical Research
No clinical references were provided for this stack yet.
More Fat Loss Stacks
HIV Lipodystrophy & Visceral Fat Reduction Protocol
A clinically-validated protocol for HIV-associated lipodystrophy using Tesamorelin alongside complementary peptides to reduce visceral adiposity, improve metabolic parameters, and support immune function in HIV-positive individuals on antiretroviral therapy.
Medically Supervised Extreme Weight Loss Protocol
Maximum-intensity peptide protocol for significant obesity (BMI 35+) combining multiple lipolytic, appetite-suppressing, and metabolic-restoring mechanisms under medical supervision.
NAFLD & Metabolic Liver Disease Protocol
A comprehensive protocol targeting non-alcoholic fatty liver disease and metabolic-associated steatohepatitis (MASH) through GLP-1 receptor agonism, AMPK activation, and mitochondrial support to reduce hepatic fat and inflammation.
Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.
Free Peptide Guide
Metabolic Syndrome & Insulin Resistance Protocol Protocol PDF
Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.
Free access. No spam. This form sends the shared peptide guide that is live today.